



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/772,063	02/04/2004	Murray S. Toas	D0932-00447	5057
8933	7590	05/18/2006	EXAMINER	
DUANE MORRIS, LLP IP DEPARTMENT 30 SOUTH 17TH STREET PHILADELPHIA, PA 19103-4196			MATZEK, MATTHEW D	
		ART UNIT	PAPER NUMBER	
			1771	

DATE MAILED: 05/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/772,063	TOAS ET AL.
	Examiner	Art Unit
	Matthew D. Matzek	1771

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 02 March 2006.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-10, 12-17 and 38-41 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-10, 12-17 and 38-41 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on 04 February 2004 is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/2/2006 has been entered.

Response to Amendment

2. The amendment dated 3/2/2006 has been fully considered and entered into the record. Claims 1-10, 12-17 and 38-41 are currently pending. Claims 1, 14 and 38-41 have been amended. The amended claims contain no new matter. The previously applied prior art rejections have been withdrawn as they failed to teach a cellulosic facing comprising at least one antifungal/antimicrobial agent present in the amount in weight of between 12-24 ppm of the dry weight of the cellulosic facing and an insulation layer adhered to said facing.

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

3. Claims 1-10, 12-17, and 38-41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fay et al. (US 2004/0185204) and further in view of Lewis et al. (US 4,105,431) and as evidenced by Furnacecompare.com and Progress-energy.com.

a. Fay et al. teach a fungi-growth inhibiting facing of a building insulation assembly including a central field portion (Abstract). The central field portion may comprise randomly oriented, entangled, glass fibers that are bound by an adhesive binder [0031].

The insulation may be faced with kraft paper with a basis weight of 30 to 40 pounds/3000 ft² [0002]. The kraft paper facing may comprise a fungicide, biocide and pesticide and may be adhered via a bituminous adhesive [0007].

b. The biocide disclosed by Fay et al. is silver zeolyte, which is commonly used in protecting food packages through its release of silver and is sold as KATHON ®, by ROHM AND HAAS®, a biocide fungi-growth inhibiting agent designed for insulation articles [0047]. As it is commonly used in protecting food packages the said biocide is presumed to be nontoxic and noncarcinogenic to humans and does not present significant toxic residue.

c. The article of Fay et al. is necessarily heat resistant to temperatures of 250 °F and molten bituminous adhesive as the applied reference teaches the application of bituminous adhesive to adhere the kraft paper facing to the insulation. Claim 16 is rejected as the bituminous layer may function as a vapor barrier [0050].

d. With regards to the claimed R-values of claim 8, these values are consistent with those of common fiberglass insulation articles known in the art, as evidenced by Furnacecompare.com. It is further noted that insulation capability (R-value) is generally given on a per inch basis and a final R-value is calculated by multiplying the R-value per inch by the total thickness of the insulation. Fiberglass batts have an average R-value of 3.25 per inch and are known to have total R-values up to 30 as evidenced by Progressive-energy.com. Fay et al. disclose a fiberglass insulation comprising fiberglass, binder and biocide, but are silent as to the R-values of said invention. It is reasonable, however to presume that since the prior art meets the physical and chemical limitation of fiberglass

batts and the body of the claim the said featured property is inherent to said insulation article thus providing the present invention the desired physical properties. This is further evidenced by the websites provided and prior Office Actions and provided along with the instant Action.

e. The publication of Fay et al. is silent as to the application of an antifungal/antimicrobial agent in the amount of between 12-24 ppm of the dry weight of the cellulosic facing.

f. Lewis et al. teach the use of novel isothiazolone compositions, which provide a spectrum of biocidal properties and are particularly effective for the control of microorganisms (Abstract). Biocides are incorporated into paper and paper products for the purpose of imparting an antimicrobial residual to control growth of fungi (mildew) and bacteria. The isothiazolones of the invention have been found to be useful as bacteriostats and mildewstats for paper and paper products. When used as paper bacteriostats and mildewstats, the isothiazolones are generally applied to the paper in aqueous solution by a conventional technique such as dipping or spraying. The 3- isothiazolone can have a wide concentration in the solution and will generally be about 0.1 to about 10,000 parts per million by weight, and preferably about 10 to about 1000 parts per million. Depending on the amount of solution uptake by the paper, the concentration of isothiazolone in the treated paper will usually range from about 0.2 to about 30,000 parts per million, and preferably about 25 to 3,000 parts per million by weight (col. 31, line 40-col. 32, line 38).

g. Since Fay et al. and Lewis et al. are from the same field of endeavor, (i.e. antimicrobial treated paper), the purpose disclosed by Lewis et al. would have been recognized in the pertinent art of Fay et al.

h. It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the insulative article of Fay, et al. with a kraft paper facing at the biocide at the level disclosed by Lewis et al. motivated by the desire to successfully create a microbial and fungicidal resistant insulative article that possesses a spectrum of biocidal properties and are particularly effective for the control of microorganisms (Abstract) at the lowest effective levels in order to minimize human exposure to said biocides. Further support for the combination of references can be found in the fact that both Fay et al. and Lewis et al. both teach the use of thiazole fungicides ([0047], Fay et al.; Example F, Lewis et al.), which is also claimed by Applicant in claim 7.

i. It should be noted that optimizing the amount or type of biocide included in the insulation article or restraining its content within set values are result effective variables. For example, manipulating the quantity of antifungal/antimicrobial agent on the cellulosic facing to attain a predetermined value or be in accordance with a standard/test. Biocide/fungicide selection is also a result effective variable. Therefore, it would have been obvious for a person having ordinary skill in the art at the time the invention was made to have made the Fay et al. invention to contain a antifungal/antimicrobial level able to pass ASTM C1338, ASTM D-2020, TAPPI Test T487, or a combination thereof.


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Matthew D. Matzek whose telephone number is (571) 272-2423. The examiner can normally be reached on 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terrel Morris can be reached on (571) 272-1478. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

mdm



NORCA TORRES
PRIMARY EXAMINER